These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39376606)

  • 1. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.
    Zhang Y; Zhou C; Liu Y; Hao Y; Wang J; Song B; Yu J
    Front Pharmacol; 2024; 15():1472648. PubMed ID: 39376606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system.
    Sun S; Zhang Y; Wu H; Peng W
    Expert Opin Drug Saf; 2024 Aug; ():1-11. PubMed ID: 39193998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).
    Liu D; Mao W; Hu B; Li X; Zhao Q; Zhang L; Hu J
    Front Pharmacol; 2024; 15():1405023. PubMed ID: 38983914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
    Zhang X; Ren X; Zhu T; Zheng W; Shen C; Lu C
    Front Pharmacol; 2024; 15():1407709. PubMed ID: 39114350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.
    He B; Zheng W
    Heliyon; 2024 Oct; 10(19):e38450. PubMed ID: 39391518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
    Shu Y; He X; Liu Y; Wu P; Zhang Q
    Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.